LON:DESTDestiny Pharma Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Destiny Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 35 -0.50 (-1.41 %) (As of 05/28/2020 04:00 PM ET) Add Compare Share Today's Range 34Now: GBX 35▼ 35.9050-Day Range 31.50MA: GBX 35.76▼ 4452-Week Range 30Now: GBX 35▼ 80Volume14,660 shsAverage Volume4,205 shsMarket Capitalization£15.35 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesOptions Chain Destiny Pharma plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel medicines for the treatment of infectious diseases in the United Kingdom. It is involved in developing XF-73 Nasal for the treatment of post-surgical staphylococcal infections; XF-73 Throat for the treatment of staphylococcal hospital/ventilator pneumonia infections; XF-70 Dermal for the treatment of skin burn wound infections of antibiotic resistant bacteria; and XF-70 Lung for the treatment of bacterial biofilm-associated infections. The company has collaboration agreement with China Medical System Holdings Limited; and research collaboration with the University of Southampton for targeting infections in diabetic foot ulcers and cystic fibrosis. The company was incorporated in 1996 and is headquartered in Brighton, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Destiny Pharma. Previous Next 2.5 Community Rank Outperform VotesDestiny Pharma has received 75 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDestiny Pharma has received 78 “underperform” votes. (Add your “underperform” vote.)Community SentimentDestiny Pharma has received 50.98% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Destiny Pharma and other stocks. Vote “Outperform” if you believe DEST will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DEST will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDestiny Pharma does not currently pay a dividend.Dividend GrowthDestiny Pharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Destiny Pharma insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Destiny Pharma is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Destiny Pharma is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDestiny Pharma has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:DEST Previous Symbol CUSIPN/A CIKN/A Webwww.destinypharma.com Phone+44-1273-704440Debt Debt-to-Equity RatioN/A Current Ratio10.68 Quick Ratio10.51Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£305,906.00 Price / Sales50.19 Cash FlowGBX 16.18 per share Price / Cash Flow2.16 Book ValueGBX 17.70 per share Price / Book1.98Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares43,865,200Market Cap£15.35 million Next Earnings DateN/A OptionableOptionable LSE:DEST Rates by TradingView Receive DEST News and Ratings via Email Sign-up to receive the latest news and ratings for DEST and its competitors with MarketBeat's FREE daily newsletter. Destiny Pharma (LON:DEST) Frequently Asked Questions How has Destiny Pharma's stock been impacted by COVID-19 (Coronavirus)? Destiny Pharma's stock was trading at GBX 35.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DEST stock has decreased by 1.4% and is now trading at GBX 35. View which stocks have been most impacted by Coronavirus. How were Destiny Pharma's earnings last quarter? Destiny Pharma PLC (LON:DEST) announced its quarterly earnings results on Wednesday, April, 29th. The company reported ($10.70) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($11.90) by $1.20. View Destiny Pharma's earnings history. Has Destiny Pharma been receiving favorable news coverage? News articles about DEST stock have been trending very negative recently, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Destiny Pharma earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutDestiny Pharma. Who are some of Destiny Pharma's key competitors? Some companies that are related to Destiny Pharma include 4d Pharma (DDDD), Actinium Pharmaceuticals (ATNM), Equillium (EQ), Sirona Biochem (SBM), Immutep (IMM), e-Therapeutics (ETX), OptiBiotix Health (OPTI), Navidea Biopharmaceuticals (NAVB), Navidea Biopharmaceuticals (NAVB), Cocrystal Pharma (COCP), Promis Neurosciences (PMN), Medlab Clinical (MDC), Protalix Biotherapeutics (PLX), Memphasys (MEM) and Emerald Health Therapeutics (EMH). View all competitors. What other stocks do shareholders of Destiny Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Destiny Pharma investors own include Abbott Laboratories (ABT), African Potash (AFPO), Aldeyra Therapeutics (ALDX), Ares Capital (ARCC), Walt Disney (DIS), Enbridge (ENB), FDM Group (FDM), First Solar (FSLR), Fortress Transprtn and Infr Investrs (FTAI) and Intel (INTC). Who are Destiny Pharma's key executives? Destiny Pharma's management team includes the following people: Mr. Neil Robert Clark, CEO & Director (Age 56)Dr. William Guy Love, Founder, Chief Scientific Officer & Director (Age 56)Mr. Shaun Claydon, CFO, Company Sec. & Director (Age 51)Dr. Jesús M González Moreno, Chief Medical Officer What is Destiny Pharma's stock symbol? Destiny Pharma trades on the London Stock Exchange (LON) under the ticker symbol "DEST." How do I buy shares of Destiny Pharma? Shares of DEST and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Destiny Pharma's stock price today? One share of DEST stock can currently be purchased for approximately GBX 35. How big of a company is Destiny Pharma? Destiny Pharma has a market capitalization of £15.35 million and generates £305,906.00 in revenue each year. What is Destiny Pharma's official website? The official website for Destiny Pharma is www.destinypharma.com. How can I contact Destiny Pharma? Destiny Pharma's mailing address is Sussex Innovation Centre Science Park Square, Falmer, BRIGHTON, BN1 9SB, United Kingdom. The company can be reached via phone at +44-1273-704440. This page was last updated on 5/28/2020 by MarketBeat.com Staff
